269 related articles for article (PubMed ID: 32598244)
1. Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age.
Vesikari T; Peyrani P; Webber C; Van Der Wielen M; Cheuvart B; De Schrevel N; Aris E; Cutler M; Li P; Perez JL
Hum Vaccin Immunother; 2020 Jun; 16(6):1280-1291. PubMed ID: 32598244
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
3. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
Vesikari T; Forsten A; Laudat F; Li P; Van Der Wielen M; Hezareh M; Perez JL; Webber C
Vaccine; 2020 May; 38(22):3902-3908. PubMed ID: 32284274
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
Quiambao B; Peyrani P; Li P; Cutler MW; Van Der Wielen M; Perez JL; Webber C
Hum Vaccin Immunother; 2020 Jun; 16(6):1272-1279. PubMed ID: 32401600
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
[TBL] [Abstract][Full Text] [Related]
6. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016; 12(1):132-9. PubMed ID: 26575983
[TBL] [Abstract][Full Text] [Related]
7. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
Klein NP; Block SL; Essink B; Barbi S; Smolenov I; Keshavan P
Vaccine; 2019 Jul; 37(32):4460-4467. PubMed ID: 31279564
[TBL] [Abstract][Full Text] [Related]
8. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
Borja-Tabora CFC; Peyrani P; Webber C; Van der Wielen M; Cheuvart B; De Schrevel N; Bianco V; Aris E; Cutler M; Li P; Perez JL
BMC Infect Dis; 2020 Jun; 20(1):426. PubMed ID: 32552685
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2012 Dec; 8(12):1892-903. PubMed ID: 23032159
[TBL] [Abstract][Full Text] [Related]
11. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
12. Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies.
Webber C; Peyrani P; Balmer P; Serra L
Vaccine; 2020 Jun; 38(27):4236-4245. PubMed ID: 32389497
[TBL] [Abstract][Full Text] [Related]
13. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
Bona G; Castiglia P; Zoppi G; de Martino M; Tasciotti A; D'Agostino D; Han L; Smolenov I
Vaccine; 2016 Jun; 34(29):3363-70. PubMed ID: 27181507
[TBL] [Abstract][Full Text] [Related]
17. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
19. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM
Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372
[TBL] [Abstract][Full Text] [Related]
20. Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.
Baxter R; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
Pediatr Infect Dis J; 2015 Nov; 34(11):1236-43. PubMed ID: 26237742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]